BioNTech SE Settles COVID-19 Dispute

This is a news story, published by Yahoo Finance, that relates primarily to Penn news.

Penn news

For more Penn news, you can click here:

more Penn news

stocks trading & speculation news

For more stocks trading & speculation news, you can click here:

more stocks trading & speculation news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about

BNTX stock

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest BNTX news, BioNTech news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

biotechnology company

TipRanks

•

BioNTech Settles Royalty Dispute with University of Pennsylvania

Summary

Nutrition label

77% Informative

BioNTech SE has reached a settlement agreement with the University of Pennsylvania over a royalty dispute related to its COVID-19 vaccine.

The agreement involves a payment of up to $467 million to Penn , which includes royalties for past sales and funding for extended research collaboration.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful